Cargando…

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare

BACKGROUND: Computer-modelling approaches have the potential to predict the interactions between different antipsychotics and provide guidance for polypharmacy. AIMS: To evaluate the accuracy of the quantitative systems pharmacology platform to predict parkinsonism side-effects in patients prescribe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kadra, Giouliana, Spiros, Athan, Shetty, Hitesh, Iqbal, Ehtesham, Hayes, Richard D, Stewart, Robert, Geerts, Hugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238161/ https://www.ncbi.nlm.nih.gov/pubmed/30232932 http://dx.doi.org/10.1177/0269881118796809

Ejemplares similares

Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2016)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

Antipsychotic polypharmacy prescribing and risk of hospital readmission
por: Kadra, Giouliana, et al.
Publicado: (2017)

Long‐term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality
por: Kadra, G., et al.
Publicado: (2018)

Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
por: Kadra, Giouliana, et al.
Publicado: (2015)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

F189. PERSONALIZED MEDICINE: ESTIMATING THE IMPACT OF GENOTYPES ON ANTIPSYCHOTIC EFFICACY USING A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
por: Geerts, Hugo, et al.
Publicado: (2018)

Toward Predicting Impact of Common Genetic Variants on Schizophrenia Clinical Responses With Antipsychotics: A Quantitative System Pharmacology Study
por: Spiros, Athan, et al.
Publicado: (2021)

Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2021)

A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson’s Disease
por: Roberts, Patrick, et al.
Publicado: (2016)

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development
por: Spiros, Athan, et al.
Publicado: (2012)

Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach
por: Geerts, Hugo, et al.
Publicado: (2020)

Clinical correlates of early onset antipsychotic treatment resistance
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Defining severity of personality disorder using electronic health records: short report
por: Monk-Cunliffe, Jonathan, et al.
Publicado: (2023)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance
por: Spiros, Athan, et al.
Publicado: (2014)

Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology
por: Geerts, Hugo, et al.
Publicado: (2015)

Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model
por: Geerts, Hugo, et al.
Publicado: (2018)

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
por: Bighelli, Irene, et al.
Publicado: (2022)

Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation
por: Lagreula, Juliette, et al.
Publicado: (2022)

Characterising the evolution of antipsychotic polypharmacy and clozapine prescribing patterns in schizophrenia patients during psychiatric hospitalisations
por: Lagreula, J., et al.
Publicado: (2022)

A biophysically realistic computer model of Alzheimer pathology to guide the development of symptomatic drugs
por: Roberts, Patrick D, et al.
Publicado: (2012)

Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action
por: Roberts, Patrick D, et al.
Publicado: (2012)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication
por: Wykes, T., et al.
Publicado: (2017)

A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer’s disease
por: Geerts, Hugo, et al.
Publicado: (2013)

Adverse outcomes associated with recorded victimization in mental health electronic records during the first UK COVID-19 lockdown
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
por: Pae, Chi-Un
Publicado: (2020)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
por: Yasui‐Furukori, Norio, et al.
Publicado: (2020)

Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
por: Lähteenvuo, Markku, et al.
Publicado: (2021)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy
por: Yazici, Esra, et al.
Publicado: (2017)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Antipsychotic prescribing in dementia
por: McLoughlin, James, et al.
Publicado: (2021)

Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method
por: Yamanouchi, Yoshio, et al.
Publicado: (2015)

Prescribing patterns of polypharmacy in Korean pediatric patients
por: Jeon, Soo-Min, et al.
Publicado: (2019)

Investigating Exposure to Violence and Mental Health in a Diverse Urban Community Sample: Data from the South East London Community Health (SELCoH) Survey
por: Kadra, Giouliana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bl2jolju75ln8k5ff7m6ucb85b